Calidi Biotherapeutics ( (CLDI) ) has shared an announcement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Calidi Biotherapeutics, a biotechnology company specializing in targeted antitumor therapies, has been notified by the NYSE that its warrants, trading under CLDI WS, will be delisted due to low trading prices. However, trading of Calidi’s common stock, CLDI, remains unaffected. The company is exploring options to appeal the decision. Calidi continues its focus on developing innovative cancer treatments through its stem cell-based platforms.
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.